1. Home
  2. SKIL vs SCYX Comparison

SKIL vs SCYX Comparison

Compare SKIL & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skillsoft Corp.

SKIL

Skillsoft Corp.

HOLD

Current Price

$9.83

Market Cap

40.2M

Sector

Technology

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$4.86

Market Cap

37.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKIL
SCYX
Founded
1998
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.2M
37.0M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
SKIL
SCYX
Price
$9.83
$4.86
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
58.5K
240.1K
Earning Date
04-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
$0.11
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.43
$0.57
52 Week High
$18.45
$5.62

Technical Indicators

Market Signals
Indicator
SKIL
SCYX
Relative Strength Index (RSI) 73.79 56.23
Support Level $9.51 $0.65
Resistance Level $10.28 $5.42
Average True Range (ATR) 0.72 0.47
MACD 0.30 0.06
Stochastic Oscillator 96.54 63.43

Price Performance

Historical Comparison
SKIL
SCYX

About SKIL Skillsoft Corp.

Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: